CYRX
VENTE TOTALE: 28 800 titres (~429 384,96 $ US)
- Insiders
- SHELTON JERRELL
- Total bought
- —
- Total sold
- $429,385
- Last activity
- 2026-08-11
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-13
Despite a moderate earnings catalyst (Q2 beat, 8% YoY revenue growth, Zacks upgrade), CYRX's severely weak financial foundation — persistent negative operating cash flows, negative interest coverage, and high cash burn…
The first sentence of the analysis written for CYRX on 2026-08-13 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 47.1% | 42.6% | 43.8% | 43.4% | 43.4% | |
| Ebit Margin | -16.9% | -40.2% | -12.2% | -120.9% | -120.9% | |
| Ebitda Margin | -1.2% | -28.4% | -2.6% | -111.8% | -111.8% | |
| Operating Profit Margin | -20.9% | -49.4% | -13.4% | -8.0% | -8.0% | |
| Pretax Profit Margin | -18.3% | -42.6% | -14.8% | -123.0% | -123.0% | |
| Continuous Operations Profit Margin | -19.3% | -42.7% | -15.7% | -123.8% | -123.8% | |
| Net Profit Margin | 44.4% | -42.7% | -15.7% | -123.8% | -123.8% | |
| Bottom Line Profit Margin | 39.9% | -46.1% | -19.1% | -127.5% | -127.5% | |
| Current Ratio | 2.174 | 5.291 | 11.732 | 14.790 | 16.263 | |
| Quick Ratio | 2.068 | 4.942 | 11.158 | 14.112 | 15.876 | |
| Solvency Ratio | 0.404 | -0.239 | -0.031 | -0.529 | -0.542 | |
| Cash Ratio | 1.144 | 0.701 | 1.016 | 0.896 | 3.262 | |
| Price To Earnings Ratio | 6.857 | -3.520 | -16.656 | -2.807 | -9.574 | |
| Price To Earnings Growth Ratio | -0.042 | -0.026 | 0.196 | 0.000 | -0.044 | |
| Forward Price To Earnings Growth Ratio | -0.042 | -0.026 | 0.196 | 0.000 | -0.044 | |
| Price To Earnings Diluted Ratio | 6.857 | -3.520 | -16.656 | -2.807 | -9.574 | |
| Price To Earnings Diluted Growth Ratio | -0.042 | -0.026 | 0.196 | 0.000 | -0.044 | |
| Price To Book Ratio | 0.956 | 0.943 | 1.552 | 1.434 | 4.234 | |
| Price To Sales Ratio | 2.728 | 1.626 | 3.198 | 3.580 | 12.208 | |
| Price To Free Cash Flow Ratio | -17.115 | -11.293 | -16.620 | -30.591 | -160.982 | |
| Price To Operating Cash Flow Ratio | -56.024 | -23.230 | -1,002.395 | -430.494 | 334.425 | |
| Debt To Assets Ratio | 0.302 | 0.356 | 0.434 | 0.420 | 0.384 | |
| Debt To Equity Ratio | 0.459 | 0.624 | 0.851 | 0.784 | 0.665 | |
| Debt To Capital Ratio | 0.315 | 0.384 | 0.460 | 0.440 | 0.400 | |
| Long Term Debt To Capital Ratio | 0.002 | 0.315 | 0.437 | 0.423 | 0.387 | |
| Financial Leverage Ratio | 1.522 | 1.750 | 1.958 | 1.869 | 1.734 | |
| Working Capital Turnover Ratio | 0.660 | 0.609 | 0.451 | 0.367 | 0.584 | |
| Operating Cash Flow Ratio | -0.039 | -0.253 | -0.017 | -0.045 | 0.191 | |
| Operating Cash Flow Sales Ratio | -0.049 | -0.070 | -0.003 | -0.008 | 0.037 | |
| Free Cash Flow Operating Cash Flow Ratio | 3.273 | 2.057 | 60.313 | 14.072 | -2.077 | |
| Debt Service Coverage Ratio | -0.021 | -3.339 | -1.339 | -52.767 | -53.443 | |
| Interest Coverage Ratio | -15.589 | -20.926 | -5.194 | -3.802 | -3.802 | |
| Short Term Operating Cash Flow Coverage Ratio | -0.046 | -1.130 | -5.081 | -30.850 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.037 | -0.065 | -0.002 | -0.004 | 0.019 | |
| Capital Expenditure Coverage Ratio | -0.440 | -0.946 | -0.017 | -0.076 | 0.325 | |
| Dividend Paid And Capex Coverage Ratio | -0.440 | -0.946 | -0.017 | -0.076 | 0.325 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -219.796 | -8.810 | -182.394 | -4.806 | -12.075 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 47.1% | ▲4.6% | ▲3.1% |
| Ebit Margin | -16.9% | ▲23.3% | ▲45.3% |
| Ebitda Margin | -1.2% | ▲27.3% | ▲50.0% |
| Operating Profit Margin | -20.9% | ▲28.5% | ▼-0.9% |
| Pretax Profit Margin | -18.3% | ▲24.3% | ▲46.1% |
| Continuous Operations Profit Margin | -19.3% | ▲23.4% | ▲45.8% |
| Net Profit Margin | 44.4% | ▲87.1% | ▲96.8% |
| Bottom Line Profit Margin | 39.9% | ▲86.0% | ▲96.0% |
| Current Ratio | 2.174 | ▼-3.116 | ▼-7.876 |
| Quick Ratio | 2.068 | ▼-2.874 | ▼-7.563 |
| Solvency Ratio | 0.404 | ▲0.643 | ▲0.591 |
| Cash Ratio | 1.144 | ▲0.442 | ▼-0.260 |
| Price To Earnings Ratio | 6.857 | ▲10.377 | ▲11.997 |
| Price To Earnings Growth Ratio | -0.042 | ▼-0.016 | ▼-0.059 |
| Forward Price To Earnings Growth Ratio | -0.042 | ▼-0.016 | ▼-0.059 |
| Price To Earnings Diluted Ratio | 6.857 | ▲10.377 | ▲11.997 |
| Price To Earnings Diluted Growth Ratio | -0.042 | ▼-0.016 | ▼-0.059 |
| Price To Book Ratio | 0.956 | ▲0.013 | ▼-0.868 |
| Price To Sales Ratio | 2.728 | ▲1.103 | ▼-1.939 |
| Price To Free Cash Flow Ratio | -17.116 | ▼-5.823 | ▲30.205 |
| Price To Operating Cash Flow Ratio | -56.024 | ▼-32.795 | ▲179.519 |
| Debt To Assets Ratio | 0.302 | ▼-0.055 | ▼-0.077 |
| Debt To Equity Ratio | 0.459 | ▼-0.165 | ▼-0.218 |
| Debt To Capital Ratio | 0.315 | ▼-0.070 | ▼-0.085 |
| Long Term Debt To Capital Ratio | 0.002 | ▼-0.313 | ▼-0.311 |
| Financial Leverage Ratio | 1.522 | ▼-0.229 | ▼-0.245 |
| Working Capital Turnover Ratio | 0.660 | ▲0.051 | ▲0.126 |
| Operating Cash Flow Ratio | -0.039 | ▲0.214 | ▼-0.006 |
| Operating Cash Flow Sales Ratio | -0.049 | ▲0.021 | ▼-0.030 |
| Free Cash Flow Operating Cash Flow Ratio | 3.273 | ▲1.216 | ▼-12.254 |
| Debt Service Coverage Ratio | -0.021 | ▲3.318 | ▲22.161 |
| Interest Coverage Ratio | -15.589 | ▲5.337 | ▼-5.726 |
| Short Term Operating Cash Flow Coverage Ratio | -0.046 | ▲1.084 | ▲7.375 |
| Operating Cash Flow Coverage Ratio | -0.037 | ▲0.028 | ▼-0.019 |
| Capital Expenditure Coverage Ratio | -0.440 | ▲0.506 | ▼-0.209 |
| Dividend Paid And Capex Coverage Ratio | -0.440 | ▲0.506 | ▼-0.209 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -219.796 | ▼-210.986 | ▼-134.220 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $480.7M | $379.2M | $758.8M | $796.8M | $2.72B | |
| Enterprise value | $460.9M | $584.6M | $1.13B | $1.20B | $3.01B | |
| EV / Sales | 2.62x | 2.51x | 4.76x | 5.37x | 13.50x | |
| EV / Op. cash flow | -53.72x | -35.81x | -1490.71x | -646.22x | 369.86x | |
| EV / Free cash flow | -16.41x | -17.41x | -24.72x | -45.92x | -178.04x | |
| EV / EBITDA | -219.80x | -8.81x | -182.39x | -4.81x | -12.07x | |
| Net debt / EBITDA | 9.43x | -3.10x | -59.75x | -1.60x | -1.16x | |
| Current ratio | 2.17x | 5.29x | 11.73x | 14.79x | 16.26x | |
| Income quality | -0.11x | 0.14x | 0.01x | 0.05x | -0.03x | |
| Graham number | $19 | — | — | — | — | |
| Graham net-net | $4 | $0 | $1 | $2 | $4 | |
| Tax burden | -243.4% | 100.2% | 106.4% | 100.6% | 100.6% | |
| Interest burden | 107.9% | 105.9% | 121.2% | 101.7% | 101.7% | |
| Working capital | $257.2M | $277.0M | $489.5M | $563.3M | $650.9M | |
| Invested capital | $542.8M | $635.2M | $909.8M | $995.9M | $1.07B | |
| Return on assets | 10.2% | -14.2% | -3.9% | -26.5% | -24.8% | |
| Operating ROA | -5.0% | -13.9% | -3.2% | -1.7% | -2.1% | |
| Return on tangible assets | 13.0% | -20.7% | -5.7% | -39.6% | -36.0% | |
| Return on equity | 15.6% | -24.8% | -7.6% | -49.6% | -42.9% | |
| Return on invested capital | -5.0% | -17.5% | -3.5% | -1.8% | -1.7% | |
| Return on capital employed | -6.7% | -18.0% | -3.5% | -1.8% | -1.7% | |
| Earnings yield | 16.3% | -26.3% | -4.9% | -34.6% | -10.1% | |
| Free cash flow yield | -5.8% | -8.9% | -6.0% | -3.3% | -0.6% | |
| Capex / Op. cash flow | -227.3% | -105.7% | -5931.3% | -1307.2% | 307.7% | |
| Capex / Depreciation | 70.4% | 56.1% | 163.3% | 106.3% | 123.5% | |
| Capex / Sales | 11.1% | 7.4% | 18.9% | 10.9% | 11.2% | |
| SG&A / Sales | 58.4% | 63.0% | 50.6% | 43.8% | 43.8% | |
| R&D / Sales | 9.7% | 7.7% | 6.6% | 7.6% | 7.6% | |
| Stock comp / Sales | 6.3% | 8.4% | 9.6% | 9.0% | 6.9% | |
| Intangibles / Total assets | 21.0% | 31.6% | 31.6% | 32.9% | 31.3% | |
| Days sales outstanding | 69d | 72d | 65d | 72d | 65d | |
| Days payables outstanding | 60d | 71d | 71d | 78d | 83d | |
| Operating cycle | 160d | 133d | 136d | 152d | 112d | |
| Cash conversion cycle | 100d | 62d | 65d | 74d | 30d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+26.8%EV / Sales ▲+4.4%EV / EBITDA ▼-2394.9%EV / Op. cash flow ▼-17.905Earnings yield ▲+0.426
Profitability
Return on equity ▲+0.404Return on assets ▲+0.244Return on invested capital ▲+0.125Return on capital employed ▲+0.113Operating ROA ▲+0.089Income quality ▼-0.252Tax burden ▼-3.436
Efficiency
Days sales outstanding ▼-2.521Days payables outstanding ▼-11.417Operating cycle ▲+27.124Cash conversion cycle ▲+38.541Capex / Sales ▲+0.037R&D / Sales ▲+0.019
Balance-sheet strength
Current ratio ▼-3.116Net debt / EBITDA ▲+12.526Working capital ▼-19852000.000Invested capital ▼-92353000.000Intangibles / Total assets ▼-0.106
Change over 5 years
Valuation
Market cap ▼-82.3%EV / Sales ▼-80.6%EV / EBITDA ▼-1720.3%EV / Op. cash flow ▼-423.580Earnings yield ▲+0.264
Profitability
Return on equity ▲+0.585Return on assets ▲+0.350Return on invested capital ▼-0.033Return on capital employed ▼-0.051Operating ROA ▼-0.029Income quality ▼-0.080Tax burden ▼-3.440
Efficiency
Days sales outstanding ▲+4.490Days payables outstanding ▼-22.877Operating cycle ▲+47.588Cash conversion cycle ▲+70.465Capex / Sales ▼-0.002R&D / Sales ▲+0.021
Balance-sheet strength
Current ratio ▼-14.088Net debt / EBITDA ▲+10.587Working capital ▼-393715000.000Invested capital ▼-526150000.000Intangibles / Total assets ▼-0.103
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-09-15 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2022-02-28 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2022-01-31 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2022-01-14 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2022-01-13 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2021-09-21 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-11-24 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-11-17 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-11-13 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-11-02 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-07-14 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-05-07 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-02-18 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-02-06 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-01-17 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-01-14 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2020-01-13 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2019-12-23 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
Recent news
- 2026-08-11 CryoPort (CYRX) Upgraded to Buy: Here''s Why CryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 2026-08-07 Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript
- 2026-08-06 CryoPort Q2 Earnings Call Highlights CryoPort NASDAQ: CYRX reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations, while reaffirming its full-year revenue outlook of $192 million to $196 million.
- 2026-08-06 CryoPort, Inc. (CYRX) Reports Q2 Loss, Beats Revenue Estimates CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.29 per share a year ago.
- 2026-08-06 Cryoport Reports Second Quarter 2026 Financial Results Second quarter revenue grew 8% year-over-year to $49.0 million Life Sciences Services revenue increased 15% year-over-year BioStorage/BioServices revenue grew 25% year-over-year Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of June 30, 2026 NASHVILLE, Tenn., Aug. 6, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.
- 2026-07-23 Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026 NASHVILLE, Tenn., July 23, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2026 on Thursday, August 6, 2026 after U.S. markets close.
- 2026-06-25 Cryoport''s IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo''s Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310 NASHVILLE, Tenn., June 25, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that Cryoport Systems'' IntegriCell® cryopreservation services have been selected by Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology for the treatment of solid tumors (SynKIR™-110) and B cell associated disorders and malignancies (SynKIR™-310).